证券代码：000516 证券简称：国际医学 编号：2024-06 西安国际医学投资股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 4.83 CNY, which represents a 2x PS valuation for 2024 [5][8]. Core Views - The company is expected to achieve a turnaround from losses to profitability, driven by significant improvements in operational metrics and revenue growth [4][8]. - The company's revenue for the first half of 2024 reached 2.42 billion CNY, a year-on-year increase of 9.53%, while the net profit attributable to shareholders was a loss of 174 million CNY, a reduction in loss by 21.89% [2][4]. Financial Performance - In H1 2024, the total outpatient and emergency service volume was 1.25 million visits, up 17.15% year-on-year, and inpatient service volume was 100,300 visits, up 16.76% [3]. - The company's two core hospitals showed significant revenue and operational improvements, with Xi'an Gaoxin Hospital achieving a revenue of 772 million CNY, a growth of 8.69%, and a net profit of 49.46 million CNY, up 43.63% [3]. - Xi'an International Medical Center Hospital reported a revenue of 1.63 billion CNY, a growth of 14.68%, with a net loss of 78.27 million CNY, reducing losses by 49.29% [3]. Profitability Metrics - The overall gross margin improved to 9.49%, an increase of 1.73 percentage points year-on-year, while the non-recurring net profit margin improved to -5.74%, an increase of 5.79 percentage points [4]. - Management expenses decreased to 11.52% of revenue, down 1.56 percentage points year-on-year, and financial expenses decreased to 3.66%, down 1.37 percentage points [4]. Future Projections - Revenue projections for 2024 to 2026 are 5.46 billion CNY, 6.28 billion CNY, and 7.07 billion CNY respectively, with net profits expected to improve significantly by 2026 [8][9]. - The company is anticipated to achieve a net profit of 1.95 billion CNY in 2025 and 3.70 billion CNY in 2026, indicating a strong recovery trajectory [8][9].

西安国际医学投资股份有限公司 投资者关系管理制度 （第十三届董事会第二次会议修订通过） 第一章 总 则 第一条 为加强公司与投资者和潜在投资者（以下统称"投资者"） 之间的信息沟通，增强投资者对公司的了解和认同，促进公司诚信自 律、规范运作，完善公司治理结构，实现公司价值最大化和股东利益 最大化。根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司投资者关系管理工作指引》《深圳证券交易所股票上市规 则》《西安国际医学投资股份有限公司章程》（以下简称：《公司章 程》）及其他相关法律、法规的规定，结合公司实际情况，制定本制 度。 第二条 本制度是公司投资者关系管理的基本行为指南。公司应 当按照本制度的精神和要求开展投资者关系管理工作。 公司控股股东、实际控制人以及董事、监事和高级管理人员应当 高度重视、积极参与和支持投资者关系管理工作。 第二章 投资者关系管理的原则和目的 第三条 投资者关系管理是指公司通过便利股东权利行使、信息 披露、互动交流和诉求处理等工作，加强与投资者之间的沟通，增进 投资者对公司的了解和认同，以提升公司治理水平和企业整体价值， 实现尊重投资者、回报投资者、保护投资者目的的相关活 ...

西安国际医学投资股份有限公司 《执行委员会工作细则》修订对照表 （2024 年 8 月） 根据《中华人民共和国公司法》《上市公司治理准则》《深圳证 券交易所股票上市规则》《西安国际医学投资股份有限公司章程》及 其他有关规定，拟对《执行委员会工作细则》中的部分条款进行修订， 具体修订内容如下： | 修订前 | 修订后 | | --- | --- | | 第一章 总则 | 第一章 总则 | | 第一条 为适应公司战略发展需要， | 第一条 为适应西安国际医学投资股 | | 规范公司的管理和运营，建立健全现代企 | 份有限公司（以下简称："公司"）战略 | | 业制度，完善公司法人治理结构，确保公 | | | 司战略管理上的有效性与质量，更好地贯 | 发展需要，规范公司的管理和运营，建立 | | 彻、执行股东大会、董事会决议，提高决 | 健全现代企业制度，完善公司法人治理结 | | 策效率和快速应变能力，根据《中华人民 | 构，确保公司战略管理上的有效性与质量， | | 共和国公司法》、《上市公司治理准则》、 | | | 《公司章程》及其他有关规定，公司特设 | 更好地贯彻、执行股东会、董事会决议， | | 立执行 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥2,420,461,714.17, representing a 9.53% increase compared to ¥2,209,788,795.81 in the same period last year[10]. - The net loss attributable to shareholders was ¥173,605,843.66, an improvement of 21.89% from a loss of ¥222,259,756.80 in the previous year[10]. - The net cash flow from operating activities increased by 28.08% to ¥525,513,894.06, up from ¥410,297,865.17 in the prior year[10]. - The total assets at the end of the reporting period were ¥10,746,800,061.61, a decrease of 5.07% from ¥11,321,135,811.77 at the end of the previous year[10]. - The net assets attributable to shareholders decreased by 5.59% to ¥3,689,515,938.42 from ¥3,908,017,195.19 at the end of the previous year[10]. - The basic earnings per share improved to -¥0.0768 from -¥0.0977, reflecting a 21.39% increase[10]. - The diluted earnings per share also improved to -¥0.0768 from -¥0.0857, showing a 10.39% increase[10]. - The gross profit margin improved to 9.49%, an increase of 1.73 percentage points from the previous year[17]. - The company reported a significant reduction in non-recurring losses, with a total of -¥34,701,237.77 for the period[13]. Operational Highlights - In the first half of 2024, the company provided emergency and outpatient services to 1,251,300 patients, a 17.15% increase compared to the same period last year[17]. - The inpatient service volume reached 100,300 patients, reflecting a 16.76% growth year-on-year[17]. - The hospital achieved a revenue of 772.35 million yuan, an increase of 8.69% year-on-year, and a net profit of 49.46 million yuan, up 43.63% from the same period last year[21]. - The emergency and outpatient service volume reached 689,700 visits, a year-on-year increase of 31.48%, while inpatient service volume was 67,900, up 22.56% year-on-year[23]. - The hospital successfully introduced 160 new talents in the first half of 2024, including 10 with doctoral or master's degrees and 8 with senior titles[20]. - The hospital completed 51 new technology and project applications, with 22 restrictive technologies registered, and published 18 academic papers, including 5 in SCI journals[20]. - The hospital organized 29 free clinic activities, serving 5,414 people, and provided free disease screening for 589 individuals[21]. - The hospital established partnerships with 76 medical institutions, adding 19 new cooperative medical institutions to expand quality medical resource coverage[21]. Strategic Initiatives - The company is expanding its medical services by integrating "Internet healthcare" and exploring "medical + AI" technology applications[16]. - The company aims to enhance its core competitiveness and sustainable profitability through internal growth and external expansion strategies[17]. - The company has become a member of the Mayo Clinic Care Network, aligning its medical quality and services with international standards[17]. - The company is developing a proton therapy center, which will be the first of its kind in Northwest China, enhancing its capabilities in cancer treatment[34]. - The company is focusing on digital transformation in healthcare, integrating advanced technologies such as artificial intelligence and telemedicine into its services[36]. - The company aims to create a comprehensive healthcare ecosystem, including a city of 20 specialized hospitals to meet diverse patient needs[34]. Financial Position - The total assets of Xi'an Gaoxin Hospital Co., Ltd. reached 2,090,340,675.25 yuan, with a net profit of 49,460,606.40 yuan, contributing over 10% to the company's net profit[60]. - Xi'an International Medical Center Co., Ltd. reported total assets of 5,095,278,375.12 yuan and a net loss of 78,273,550.40 yuan during the reporting period[60]. - The company has established a comprehensive medical service platform with a capacity of 10,000 beds across its three major medical campuses[17]. - The company has a strong emphasis on high-quality medical service management, ensuring patient dignity and healthcare provider respect[33]. - The company has achieved full coverage of medical insurance across its institutions, enhancing its operational efficiency and service quality[43]. Environmental Compliance - The company is compliant with environmental regulations, holding valid discharge permits for its hospitals, with the latest permit for Xi'an International Medical Center Hospital valid until March 28, 2026[74]. - The company adheres to various pollution discharge standards, including those for waste gas, wastewater, and noise, ensuring no exceedance of emission limits reported[74]. - The company is focused on maintaining compliance with air and water quality standards as part of its operational strategy[75][76]. - The company emphasizes environmental sustainability and has made continuous investments in environmental protection and governance[82]. Shareholder and Governance - The company actively protects the rights of shareholders, investors, patients, and suppliers, ensuring compliance with relevant laws and regulations[83]. - The company has implemented a comprehensive human resources management system to safeguard employee rights and benefits[83]. - The company held its first temporary shareholders' meeting on March 21, 2024, with an investor participation rate of 32.32%[65]. - The company has no overdue commitments or non-operating fund occupation by controlling shareholders or related parties during the reporting period[84]. - The company reported no significant litigation or arbitration matters during the reporting period, with a total amount involved in ongoing cases of 1,227.23 million CNY[87]. Future Outlook - The company provided a future outlook with a revenue guidance of 10% growth for the next quarter, aiming to reach 8,138 million[104]. - The company plans to implement a new digital platform aimed at improving customer experience and operational efficiency, with an expected investment of 490 million[104]. - The company plans to continue its market expansion and product development strategies in the upcoming periods[149].

西安国际医学投资股份有限公司 《对外担保管理制度》修订对照表 （2024 年 8 月） 根据《中华人民共和国民法典》《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司监管指引第 8 号—上市公司资金往 来、对外担保的监管要求》《深圳证券交易所股票上市规则》等法律、 法规、规范性文件以及《西安国际医学投资股份有限公司章程》的有 关规定，拟对《对外担保管理制度》中的部分条款进行修订，具体修 订内容如下： | 修订前 | 修订后 | | --- | --- | | 第一章 总则 | 第一章 总则 | | 第一条 为加强西安开元投资集团股 | 第一条 为加强西安国际医学投资股 | | 份有限公司（以下简称"公司"）内部控 | 份有限公司（以下简称："公司"）内部 | | 制，规范公司对外担保行为，维护投资者 | 控制，规范公司对外担保行为，维护投资 | | 利益，有效控制公司对外担保风险，保证 | | | 公司资产安全，促进公司健康、稳定地发 | 者利益，有效控制公司对外担保风险，保 | | 展，根据《公司法》、《证券法》、《担 | 证公司资产安全，促进公司健康、稳定的 | | 保法》等法律法规以及中国证监 ...

西安国际医学投资股份有限公司 《董事会秘书工作细则》修订对照表 （2024 年 8 月） 根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》 《西安国际医学投资股份有限公司章程》（以下简称："公司章程"） 及其他有关规定，拟对《董事会秘书工作细则》中的部分条款进行修 订，具体修订内容如下： | 修订前 | 修订后 | | --- | --- | | 第一章 总则 | 第一章 总则 | | 第一条 为促进西安开元投资集团股 | 第一条 为促进西安国际医学投资股 | | 份有限公司（以下简称：公司）的规范运 | 份有限公司（以下简称："公司"）的规 | | 作，明确董事会秘书的职责权限，充分发 | 范运作，明确董事会秘书的职责权限，充 | | 挥董事会秘书的作用，根据《中华人民共 | 分发挥董事会秘书的作用，根据《中华人 | | 和国公司法》（以下简称：《公司法》）、 | 民共和国公司法》（以下简称：《公司法》）、 | | 《深圳证券交易所股票上市规则》（以下 | 《深圳证券交易所股票上市规则》（以下 | | 简称：《上市规则》）、《西安开元投资 | 简称：《上市规则》）、《西安国际医学 | | 集团股份 ...

| 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 | 上市公司核算 | 2024 年初占用资金 | 2024 年半年度占 | 2024 年半年度占用 | 2024 年半年度偿还 | 2024 年半年度末 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 的关联关系 | 的会计科目 | 余额 | 用累计发生金额 （不含利息） | 资金的利息（如有） | 累计发生额 | 占用资金余额 | 占用形成原因 | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 前控股股东、实际控制人及其附属企 | | | | | | | | | | | | 业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 其他关联方及其附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 总 计 | | | ...

西安国际医学投资股份有限公司 《投资者关系管理制度》修订对照表 （2024 年 8 月） 根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司投资者关系管理工作指引》《深圳证券交易所股票上市规则》 《西安国际医学投资股份有限公司章程》及其他相关法律、法规的规 定，拟对《投资者关系管理制度》中的部分条款进行修订，具体修订 内容如下： | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------ ...

西安国际医学投资股份有限公司 执行委员会工作细则 （第十三届董事会第二次会议修订通过） 第一章 总 则 第一条 为适应西安国际医学投资股份有限公司（以下简称"公 司"）战略发展需要，规范公司的管理和运营，建立健全现代企业制 度，完善公司法人治理结构，确保公司战略管理上的有效性与质量， 更好地贯彻、执行股东会、董事会决议，提高决策效率和快速应变能 力，根据《中华人民共和国公司法》《上市公司治理准则》《深圳证 券交易所股票上市规则》《西安国际医学投资股份有限公司章程》（以 下简称："公司章程"）及其他有关规定，结合公司的实际情况，公 司特设立执行委员会，并制定本工作细则。 第二条 执行委员会在股东会、董事会闭会期间负责贯彻执行股 东会、董事会决定的各项决议，决定和审议公司政策，对重大日常工 作和活动作出协调性的规定，并在董事会授权范围内负责对公司的投 资等事项，或突发、紧急、临时性重大事项进行决策。 第二章 人员组成 （三）代表公司董事会进行对外重大业务谈判，处理公司投资、 融资等事项； （四）在不超过公司最近一期经审计的净资产的10％的范围内决 定对外投资、资产的购买、处置和对外捐赠等事项，根据公司发展的 需要 ...